Reckitt CEO's $17B Predicament Post author:Sam Post published:December 26, 2017 Post category:BioPharma 2018 is the year for Rakesh Kapoor to show he’s worth it. Source: BioSpace You Might Also Like SoCal's Vical Terminates 54% of Workforce to Focus Resources on Two Clinical Programs January 30, 2018 3 Top Diabetes Biotechs to Buy Into Right Now November 26, 2017 Dermira’s Acne Medication Olumacostat Glaseretil Tanks in Two Phase III Trials March 4, 2018
SoCal's Vical Terminates 54% of Workforce to Focus Resources on Two Clinical Programs January 30, 2018
